Ivan Kairatov is a Biopharma expert with deep knowledge of technology and innovation in the industry, with experience in research and development. Today, we discuss the recent FDA approval of adaptive deep brain stimulation (aDBS) as a new treatment option for Parkinson’s disease. Can you explain
In this interview, we are pleased to welcome Ivan Kairatov, a Biopharma expert with deep knowledge of tech and innovation in the industry and extensive experience in research and development, particularly in gene therapy for sensory disorders. Today, Ivan will share insights on the recent positive
Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide, primarily due to its high potential for metastasis and the related challenges in treatment. These challenges often include drug toxicity, tumor recurrence, and development of drug resistance due to genetic
Recent scientific advancements have shed new light on the implications of PIK3CA mutations in cancer treatment, prompting significant interest in developing targeted therapies to enhance drug efficacy while mitigating adverse effects. The PIK3CA gene, which encodes the p110α subunit of
Ivan Kairatov is a Biopharma expert, with profound knowledge in technology and innovation in the medical industry, and extensive experience in research and development. Today, we'll delve into a study from the University of Colorado Anschutz Medical Campus, discussing its significance for diabetes
Mirum Pharmaceuticals recently made headlines as they secured FDA approval for Ctexli, also known as chenodiol, as the first treatment for cerebrotendinous xanthomatosis (CTX). CTX, a rare genetic lipid storage disease, affects an estimated 3 to 5 individuals per 100,000. This approval came after a
